Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Next Previous
X
Search
Trial Profile

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NTLA-2002 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms NTLA-2002
  • Sponsors Intellia Therapeutics

    • Most Recent Events

    • 08 Aug 2024 According to Intellia Therapeutics media release, company announced positive topline results
    • 08 Aug 2024 According to Intellia Therapeutics media release, Primary endpoint (Number of HAE attacks per month (Weeks 1-16)) has been met.
    • 06 Jun 2024 Planned End Date changed from 15 Dec 2025 to 31 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top